||3R01CA069619-03S1 Interpret this number
||Univ Of California At San Francisco
||Fertility Drugs and Ovarian Cancer
DESCRIPTION: (Adapted from Investigator's Abstract) The primary aim of this
study is to determine if infertile women exposed to ovulation-inducing
agents (OIAs) are at increased risk for ovarian cancer as compared to
infertile women not exposed to OIAs. The cohort consists of 74,640 women
seen for infertility services by one of 15 infertility clinics in California
between 1965 and 1995. Tracing and linkage information will be abstracted
from computerized listings or medical records for all women comprising the
study cohort to verify state of residence. Linkage with state and local
tumor registries will be done to identify incident cases of ovarian cancer.
Assuming a relative risk of 3, they expect to obtain 267 cases of ovarian
cancer. An age-stratified random sample of 2,670 cohort members will serve
as the subcohort. Full medical record review and telephone interviews will
be conducted for ovarian cancer cases and all subcohort members to gather
complete information on OIA exposure as well as reproductive history, health
status, and infertility treatment-related conditions. The relationship
between OIAs and ovarian cancer will be analyzed using the proportional
hazards regression model, adjusted for the case-cohort design. Analyses
will consider differences in risk according to formulation, dose, and
duration of OIAs as well as among subgroups defined by infertility etiology,
parity, anovulation, and demographic characteristics.
A second aim of this study is to determine if there is a difference in
ovarian cancer risk between infertile women treated with OIAs, presumed
fertile women treated with OIAs for timed conception (e.g., because of
male-factor infertility or for donor insemination), and fertile women
treated with OIAs for the purposes of ovum donation to determine the
possible independent effects of infertility and OIAs on ovarian cancer risk.
The groups will be comprised of infertile women exposed to OIAs from the
above cohort, presumed fertile women exposed to OIAs from participating
infertility centers, and 767 ovum donors. Data on ovarian cancer incidence
and OIA exposure will be collected and analyzed in the same manner described
above. The third aim of this study is to use the same methods to determine
if there is a difference in risk for breast and uterine corpus cancers
between infertile women exposed to OIAs, infertile women not exposed to
OIAs, and fertile women exposed to OIAs.
None. See parent grant details.